ANGLE PLC

Management Reports • May 28, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6086F

Angle PLC

28 May 2013

For immediate release	28 May 2013

ANGLE plc

("ANGLE" or "the Company")

PARSORTIX MANUFACTURER APPOINTED      

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that the Company has appointed a manufacturer for its Parsortix non-invasive cancer diagnostic product.

Following a thorough selection process, ANGLE has selected Cogent Technology Limited ("Cogent") to manufacture the Parsortix automated machine. The consumable for the system, the Parsortix cassette, will continue to be produced by specialist nano-manufacturer thinXXS.

The Parsortix automated machine can be configured either for the counting and identification of circulating tumour cells (CTCs) in the blood, or for the capture and harvesting of the CTCs from the blood for further molecular analysis.

The appointment of Cogent enables ANGLE to increase manufacturing volumes to meet expected demand, initially for the research market and then for the clinical market. Cogent will provide robust manufacturing services and supply chain management in accordance with the necessary quality assurance methods for electro-mechanical products destined for critical markets such as healthcare.  

The Company's out-sourcing strategy continues to be the best way to deliver the roll out of Parsortix, without the associated investment and running costs of undertaking these activities in house.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"The appointment of a specialist, larger scale manufacturer with the necessary quality systems to support regulatory authorisation is an important step towards positioning ANGLE so that it is capable of meeting substantial market demand in the future. We have already initiated the roll out of Parsortix into the research market and look forward to continuing the roll out into the clinical market once regulatory authorisations have been received." 

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Adrian Hargrave, Stephen Keys (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles  www.buchanan.uk.com	020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUBARROUAVUUR